Breaking News, Promotions & Moves

Jubilant Therapeutics Appoints New President & CEO

Daniel J. O'Connor brings more than 30 years of leadership experience in biotechnology and oncology

Author Image

By: Charlie Sternberg

Associate Editor

Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Daniel J. O’Connor as President & Chief Executive Officer. “We are delighted to welcome Dan as CEO of Jubilant Therapeutics Inc.,” said Hari S Bhartia, Chairman, Jubilant Therapeutics Inc. “His extensive experience in building and scaling biopharmaceutical companies, combined with his deep expertise in oncology and strategic partnerships, will be instrumental in advancing our miss...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters